Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - RBC Capital has raised its price target on Gilead Sciences (NASDAQ:GILD) to $98.00 from $96.00 while maintaining a Sector Perform rating on the stock. The biotechnology giant, currently valued at $148.48 billion, is trading near its 52-week high of $119.96. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.
The price target increase follows Gilead’s solid second-quarter performance, which showed beats across key HIV and PrEP franchises, though some programs less important to long-term growth missed expectations.
Gilead also raised its guidance, and its Yeztugo launch appears to be on track, though RBC notes the performance is unlikely to surprise investors who follow third-party prescription trends.
RBC Capital describes Gilead as a "solid story" with a healthy core HIV franchise and near to medium-term launches, including Yeztugo and anito-cel, that can drive enthusiasm.
The firm cautions that after a significant stock run, PrEP expectations may be difficult to materially surpass, and exposure to potential policy headwinds may be underappreciated by investors.
In other recent news, Gilead Sciences has reported second-quarter 2025 earnings that exceeded Wall Street expectations, with an earnings per share (EPS) of $2.01, surpassing the forecasted $1.96. The company’s revenue also outperformed projections, reaching $7.1 billion compared to the anticipated $6.97 billion. This strong performance was largely driven by the company’s HIV segment, prompting management to raise its full-year guidance to project 3% year-over-year growth. Analysts have responded positively to these results, with TD Cowen raising its price target for Gilead Sciences to $115, while maintaining a Buy rating. Morgan Stanley (NYSE:MS) also increased its price target to $143, citing the strength in the HIV business and maintaining an Overweight rating. Truist Securities upgraded Gilead Sciences from Hold to Buy, setting a new price target of $127 due to the robust quarterly performance. UBS adjusted its price target to $112, keeping a Neutral rating following the strong earnings report. These developments highlight the positive momentum in Gilead’s financial performance and the confidence analysts have in its future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.